MedTrace Logo

Phase II Randomized Bilateral Comparison of Topical Targretin Gel 1% in Alopecia Areata

NCT00063076 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 46

Last updated 2012-08-02

No results posted yet for this study

Summary

The goal of this clinical research study is to find the most effective dose of Targretin® (bexarotene) Gel 1% that can be given to patients as a treatment for alopecia areata. The safety and tolerability of this drug will also be studied.

Objectives:

1. Determine the safety and tolerability of Targretin® Gel 1% in the treatment of patients with alopecia areata.
2. Determine the efficacy of Targretin® Gel 1% in the treatment of patients with alopecia areata.

Conditions

Interventions

DRUG

Targretin Gel 1%

Alopecia lesions on one-half of the head including facial hair treated, and other half on head serves as control (untreated). Starting dose once every day till Week 3 then escalate to twice a day.

Sponsors & Collaborators

  • Ligand Pharmaceuticals

    collaborator INDUSTRY

  • M.D. Anderson Cancer Center

    lead OTHER

Principal Investigators

  • Madeleine Duvic, MD · UT MD Anderson Cancer Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2003-05-31
Primary Completion
2006-10-31
Completion
2007-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00063076 on ClinicalTrials.gov